Vasodilator‐stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events
Open Access
- 7 May 2007
- journal article
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 5 (8), 1630-1636
- https://doi.org/10.1111/j.1538-7836.2007.02609.x
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Long-Term Cost Effectiveness of Early and Sustained Dual Oral Antiplatelet Therapy With Clopidogrel Given for Up to One Year After Percutaneous Coronary InterventionJournal of the American College of Cardiology, 2005
- Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseasesJournal of Thrombosis and Haemostasis, 2004
- Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial InfarctionCirculation, 2004
- Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventionsPublished by Oxford University Press (OUP) ,2004
- Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator‐stimulated phosphoprotein phosphorylationCatheterization and Cardiovascular Interventions, 2003
- Clopidogrel for Coronary StentingCirculation, 2003
- Identification of the platelet ADP receptor targeted by antithrombotic drugsNature, 2001
- A Comparison of Balloon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery DiseaseNew England Journal of Medicine, 1994
- Ticlopidine and subcutaneous heparin as an alternative regimen following coronary stentingCatheterization and Cardiovascular Diagnosis, 1994
- Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patientsThrombosis Research, 1993